AOU Città della Salute e della Scienza di Torino – PO Molinette

Titolo:	ROAD- Real-World Outcomes of DArolutamide, ADT, with or without Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer.
Patologia:	Carcinoma prostatico metastatico ormonosensibile (mHSPC)
Tipo di Studio:	Osservazionale prospettico, open label, multicentrico
Fase:	N.A.
Principali criteri di inclusione:	Male patient with a diagnosis of mHSPC Male aged ≥18 years Histologically or cytologically confirmed adenocarcinoma of prostate. Participants may have begun ADT (up to 120 days prior to enrollment) Metastatic disease by conventional or new generation imaging Decision to initiate treatment with darolutamide with, or without docetaxel was made as per investigator's routine treatment practice prior to enrollment in the study Life expectancy of ≥3 months based on clinical judgment
Principali criteri di esclusione:	Partecipation in an investigational program with interventions outside of routine clinical practice Contra-indications according to the local marketing authorization Any prior treatment with second-generation androgen receptor (AR) inhibitors such as enzalutamide, apalutamide, or other investigational AR inhibitors, cytochrome P17 enzyme inhibitor such as abiraterone acetate or other investigational CYP 17 as antineoplastic treatment for prostate cancer Prior hormone therapy in the metastatic setting Treatment with darolutamide initiated more than 7 days prior to enrollmen
Sede e contatti	S.C. Oncologia 1U, Presidio Molinette, A.O.U. Città della Salute e della Scienza di Torino Dott.ssa Ilaria Depetris – PI 0116336894 trialsmolinette@gmail.com